TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
17/11/2021
Voltar para busca
Dado oficial do USPTO
KNACK PHARMACEUTICALS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
KNACK PHARMACEUTICALS
ST13
US500000087817010Classe
5
Pedido
87817010
Registro
6540123
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
39
Atualização mais recente
17/11/2021
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
01/03/2018
Data de registro
26/10/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
26/10/2021
Última transação
26/10/2021
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
01/08/2021
Primeiro uso no comércio
01/08/2021
Código do desenho
4
Tipo de titular
03
Localização do titular
New York City, NY, US
Examinador
MAYES, LAURIE ANN
Unidade examinadora
L10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
KNACK PHARMACEUTICALS, INC.
Representantes
Tomas Maria Casalins Fox Horan & Camerini LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of epilepsy disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tractgastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of skin diseasesallergies and rheumatic disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of Alzheimer; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of ophthalmic related disorders and diseases; Pharmaceutical preparations for the treatment and prevention of musculoskeletal related diseases and disorders; Pharmaceutical preparations for for the treatment and prevention of metabolicendocrine and kidney related diseases and disorders; Pharmaceutical preparations for the support and promotion of bone strength and health; Pharmaceutical preparations for the treatment of bone disorders and bone diseases; Pharmaceutical preparations for the treatment of toxic effects; Pharmaceutical preparations for use as injectable anesthetics; Pharmaceutical preparations for use as contraceptives; Pharmaceutical preparations for fertility enhancement purposes; Pharmaceutical preparations for use in hormone replacement therapy; Pharmaceutical preparations for the prevention and treatment of hormone disorders and deficiencies; Pharmaceutical preparations for inducing labor and facilitating nursing; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for for the prevention and treatment of nausea and vomiting; Pharmaceutical preparations for the prevention and treatment of aids-related disorders and diseases; Pharmaceutical preparations for for the treatment and prevention of viral and bacterial infections; Pharmaceutical preparationsinjectable contraceptives
Publicações
Histórico de despachos e eventos da marca no USPTO.
39 publicações encontradas
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
17/11/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
17/11/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
17/11/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
26/10/2021
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
18/09/2021
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
17/09/2021
SUPC
STATEMENT OF USE PROCESSING COMPLETE
16/09/2021
IUAF
USE AMENDMENT FILED
10/09/2021
EISU
TEAS STATEMENT OF USE RECEIVED
10/09/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
17/03/2021
EX5G
SOU EXTENSION 5 GRANTED
16/03/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
16/03/2021
EXT5
SOU EXTENSION 5 FILED
02/03/2021
EEXT
SOU TEAS EXTENSION RECEIVED
02/03/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
08/08/2020
EX4G
SOU EXTENSION 4 GRANTED
06/08/2020
EXT4
SOU EXTENSION 4 FILED
06/08/2020
EEXT
SOU TEAS EXTENSION RECEIVED
06/08/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
07/03/2020
EX3G
SOU EXTENSION 3 GRANTED
05/03/2020
EXT3
SOU EXTENSION 3 FILED
05/03/2020
EEXT
SOU TEAS EXTENSION RECEIVED
05/03/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
30/08/2019
EX2G
SOU EXTENSION 2 GRANTED
28/08/2019
EXT2
SOU EXTENSION 2 FILED
28/08/2019
EEXT
SOU TEAS EXTENSION RECEIVED
28/08/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/03/2019
EX1G
SOU EXTENSION 1 GRANTED
01/03/2019
EXT1
SOU EXTENSION 1 FILED
01/03/2019
EEXT
SOU TEAS EXTENSION RECEIVED
01/03/2019
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
11/09/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
17/07/2018
PUBO
PUBLISHED FOR OPPOSITION
17/07/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
27/06/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
13/06/2018
DOCK
ASSIGNED TO EXAMINER
13/06/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/03/2018
NWAP
NEW APPLICATION ENTERED
05/03/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace KNACK PHARMACEUTICALS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.